Buprenorphine
History
Buprenorphine was synthesized at the British pharmaceutical company Reckitt and Colman (now Indivior) in 1969 by John Lewis and colleagues, initially as a research compound (designated Reckitt's RX 6029-M) intended as a more potent analgesic than morphine. The partial-agonist character was recognized early in pharmacology studies and was initially considered a drawback for analgesic potency relative to full agonists.
FDA approval as Buprenex (IV/IM) for moderate-to-severe acute pain was granted in 1981. The compound was Schedule V at this time, reflecting its low diversion potential in injectable form.
The pivot to MOUD came from a series of clinical trials in the 1990s demonstrating buprenorphine's efficacy in opioid use disorder. Walter Ling, Eric Strain, and others established that buprenorphine could be administered sublingually with weekly or less-frequent dosing in stable patients, contrasting with methadone's daily-witnessed-dosing OTP model.[citation needed]
The Drug Addiction Treatment Act of 2000 (DATA 2000) created the X-waiver framework, allowing physicians to obtain a separate DEA waiver to prescribe buprenorphine for OUD in office-based settings outside the OTP infrastructure. FDA approval of Subutex (buprenorphine sublingual) and Suboxone (buprenorphine/naloxone sublingual) for MOUD followed in 2002. The naloxone in Suboxone is poorly absorbed sublingually (the intended therapeutic route) but is well-absorbed if the tablet is injected, providing a deterrent against diversion to injection.
Buprenorphine was rescheduled from V to III in 2002, reflecting recognition of its abuse potential in MOUD-naive populations.
The Mainstreaming Addiction Treatment (MAT) Act, passed as part of the Consolidated Appropriations Act 2023 in December 2022 and implemented in 2023, abolished the DEA X-waiver requirement. Any DEA-licensed prescriber can now prescribe buprenorphine for OUD without separate certification, removing a major barrier that had been criticized as artificially constraining MOUD access.
Long-acting formulations have expanded the buprenorphine treatment landscape: Probuphine (6-month subdermal implant) was approved 2016 and discontinued 2020; Sublocade (monthly SC depot) was approved 2017 and remains in use; Brixadi (weekly or monthly SC depot) was approved 2023.Experience
Log in to add your own experience.
Problems
<problem>: unknown ref "moderate-severe-pain"
Titration strategies
Day 1: 2-4 mg sublingual; observe 60-90 minutes for response and any precipitated withdrawal. Second dose 4 mg if comfortable. Total day 1 typically 8-16 mg. Day 2: Titrate to comfort, typically 8-16 mg.
Day 3+: Maintenance 8-24 mg/day; typical effective range 16 mg/day.Sample schedule (variations exist): Day 1: 0.5 mg buprenorphine BID. Day 2-3: 1 mg BID. Day 4-5: 2 mg BID. Day 6-7: 4 mg BID. Day 8+: stop full agonist, continue buprenorphine 8-24 mg/day.
The Bernese approach largely avoids precipitated withdrawal but requires careful patient selection and monitoring.Effects
- <effect>: unknown ref "analgesia"
- <effect>: unknown ref "craving-suppression"
- <effect>: unknown ref "precipitated-withdrawal"
- Constipation no reports yet no reports yetLess severe than with full agonists but still present.Did you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- <effect>: unknown ref "sedation"
- Nausea no reports yet no reports yetCommon at induction; usually self-limited.Did you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- Sweating / diaphoresis no reports yet no reports yetLess than methadone but present.Did you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- <effect>: unknown ref "dental-caries"
- <effect>: unknown ref "hypogonadism"
- Respiratory depression no reports yet no reports yetPresent but with CEILING effect; full mu-agonist overdose lethality reduced. Combination with benzodiazepines, alcohol, or other CNS depressants removes the ceiling protection - this is the only combination scenario where buprenorphine overdose mortality approaches full-agonist levels.Did you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
- QT prolongation no reports yet no reports yetModest; clinically less concerning than methadone but present.Did you experience this?How often have you seen this?How was it? (-100 worst, +100 best)How was it? (-100 worst, +100 best)
Pharmacokinetics
Absorption
Sublingual ~30% bioavailability (primary therapeutic route). Oral swallowed bioavailability poor (~10-20%) due to extensive first-pass metabolism; not used therapeutically. Buccal (Belbuca) ~50% bioavailability. Transdermal (Butrans) bypasses first-pass entirely; steady-state in ~3 days.[1]Distribution
Plasma protein binding ~96% (alpha-1-acid glycoprotein primarily). Highly lipophilic; large volume of distribution. Crosses blood-brain barrier readily and placenta in moderate amounts. Excreted in breast milk at low levels generally compatible with breastfeeding in stable maintained patients.[1]Metabolism
Hepatic N-dealkylation primarily via CYP3A4 to norbuprenorphine (active metabolite, weaker mu-agonist + NOP agonist). Also glucuronidation by UGT1A1, UGT1A3, UGT2B7. Norbuprenorphine accumulates with chronic dosing and contributes substantially to clinical effect. Buprenorphine itself is not a clinically significant CYP3A4 inhibitor or inducer.[1]Elimination
Primarily fecal/biliary as glucuronide conjugates of parent and metabolites (~70%); urinary ~30%. Half-life sublingual 24-42 hours; norbuprenorphine 24-48 hours. The long half-life supports every-other-day or three-times-weekly dosing in stable MOUD patients.[1]Pharmacodynamics
Buprenorphine is a partial mu-opioid agonist with high mu-receptor affinity (Ki ~0.2 nM) and slow dissociation kinetics (receptor residency time hours rather than minutes). The high affinity means buprenorphine displaces lower-affinity opioids from the receptor (the precipitated-withdrawal risk in opioid-tolerant patients) and blocks subsequently administered opioids (the MOUD mu-receptor blockade benefit). The partial agonism means receptor saturation produces less mu-signaling than a full agonist would; this is the basis for the ceiling effect on respiratory depression that distinguishes buprenorphine safety from methadone and other full agonists.
Buprenorphine is also a kappa-opioid receptor antagonist (which may contribute to antidepressant effect and may attenuate stress-induced relapse in OUD) and a partial agonist at the NOP/ORL1 (nociceptin) receptor. The combined receptor profile is distinct from morphine-class full agonists and contributes to the medicine's unique clinical profile.
Norbuprenorphine, the major active metabolite, is itself a partial mu-agonist with lower potency than parent, but accumulates and contributes substantially to net pharmacological effect at steady state.Interactions
The clinically important interactions for prescribers:
- Benzodiazepines + buprenorphine (boxed warning). The ceiling effect on respiratory depression is lost when combined with benzodiazepines, alcohol, or other CNS depressants. Concurrent benzo + buprenorphine deaths constitute a substantial fraction of MOUD population mortality. The FDA explicitly does NOT recommend withholding buprenorphine MOUD from patients on benzodiazepines (untreated OUD is more dangerous than benzo-buprenorphine combination), but counseling and benzodiazepine taper should be pursued where feasible.
- Full mu-agonist opioids. Buprenorphine blocks full-agonist effect at the mu-receptor. Patients on buprenorphine MOUD who require opioid analgesia for acute pain (e.g., post-surgical) need specialist consultation; options include continuing buprenorphine + adding short-acting opioid above the buprenorphine "block," or briefly holding buprenorphine, or using non-opioid alternatives.
- CYP3A4 strong inhibitors. Ritonavir, clarithromycin, ketoconazole, itraconazole: increase buprenorphine exposure modestly; clinical adjustment usually not required given partial-agonist safety margin.
- CYP3A4 strong inducers. Rifampin, phenytoin, phenobarbital, carbamazepine, efavirenz, St John's wort: reduce buprenorphine exposure; may need dose increase.
- Mixed agonist-antagonists (nalbuphine, butorphanol). Precipitate withdrawal in buprenorphine-maintained patients.
- Pure antagonists (naloxone, naltrexone). Naloxone reverses buprenorphine respiratory depression but high doses or continuous infusion are typically needed due to the high mu-receptor affinity and slow dissociation. Naltrexone administration to a buprenorphine-maintained patient precipitates withdrawal.
- QT-prolonging medications. Modest additive effect; clinically less concerning than methadone.
- Serotonergic medications. Buprenorphine has weak SRI activity; serotonin syndrome risk with strong serotonergic medications exists but is less commonly observed than with tramadol or full agonists like meperidine.
Pregnancy and lactation
Buprenorphine is endorsed by ACOG (Committee Opinion 711) and ASAM as first-line MOUD in pregnancy alongside methadone. The MOTHER trial (Jones HE et al, N Engl J Med 2010, PMID 21142534) compared buprenorphine vs methadone in pregnant women with OUD and found comparable maternal outcomes with somewhat milder neonatal abstinence syndrome (NAS) and shorter NAS treatment duration in the buprenorphine group. The mono-buprenorphine formulation (Subutex generic) was historically preferred in pregnancy over the naloxone combination (Suboxone) due to theoretical concerns about naloxone passage; modern data support both formulations as safe and many programs no longer distinguish.
Buprenorphine clearance may modestly increase during pregnancy; dose adjustment is sometimes needed in the third trimester. Buprenorphine is excreted in breast milk at low concentrations (M/P ratio ~1, but absolute infant exposure is low) and breastfeeding is generally encouraged in stable maintained patients per ACOG and the Academy of Breastfeeding Medicine.
NAS expected with chronic buprenorphine exposure during pregnancy; typically milder and shorter-duration than methadone-NAS; managed in NICU with non-pharmacologic supportive care + opioid taper (morphine or methadone) for severe cases.Monitoring
Boxed warning items: respiratory depression (especially with concurrent benzo/CNS depressant), addiction/abuse/misuse, NAS.
Specific monitoring:
- Pre-induction OUD assessment + COWS scoring before first dose (to confirm withdrawal state, avoid precipitated withdrawal)
- LFTs at baseline + every 6-12 months (buprenorphine hepatotoxicity is rare but documented; monitor especially in hepatitis C coinfected patients)
- PDMP review at intake + regularly per state requirements
- Urine drug screening per program protocol
- Dental examination at intake + annually (FDA 2022 warning regarding sublingual-film dental caries)
- Pregnancy testing in females of reproductive potential at intake; counseling re continuation of MOUD during pregnancy
Patient counseling
Precipitated withdrawal at induction. If you take buprenorphine while you still have substantial opioid in your system, you can have severe sudden withdrawal. We will time your first dose to when you are already in moderate withdrawal (or use a microdosing protocol to avoid this).
Benzodiazepines and alcohol. Buprenorphine has a "ceiling" on respiratory depression that makes it safer than full opioids - BUT this ceiling is lost when you combine buprenorphine with benzodiazepines or alcohol. The combination can be fatal. Talk with your prescriber about any benzodiazepine, sedative, or alcohol use.
Acute pain. If you need pain medicine for surgery or injury while on buprenorphine, your provider needs to know you are on buprenorphine. The buprenorphine blocks other opioids; managing acute pain requires specialist guidance.
Other opioids. Buprenorphine blocks the effect of other opioids. If you try to use heroin or other opioids on buprenorphine, you typically won't feel them - this is part of how buprenorphine protects you. Trying to overcome the block with very high doses can produce overdose when the buprenorphine eventually wears off (after stopping treatment).
Sublingual administration. Place the film or tablet under the tongue and let it dissolve fully (usually 5-10 minutes). Do NOT swallow it - swallowed buprenorphine has very low absorption. Do NOT chew or talk while it dissolves. Rinse your mouth with water after to protect your teeth (FDA dental warning 2022).
Driving and machinery. Do not drive after the first dose or after any dose increase until you know how buprenorphine affects you. Once stable on a steady dose, most patients can drive safely.
Pregnancy. Buprenorphine is one of the safest MOUD options during pregnancy. If you become pregnant, do NOT stop abruptly - this can harm the pregnancy. Talk with your provider.
Naloxone awareness. Keep naloxone (Narcan) available at home; educate household members. Naloxone reverses opioid overdose. Because buprenorphine has high mu-receptor affinity, multiple naloxone doses may be needed; emergency care is essential.
Discontinuation. Buprenorphine withdrawal is typically milder than full-agonist withdrawal but can be prolonged due to the long half-life. Slow taper recommended; do not stop abruptly after long-term use.Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.